Epoxomicin A potent chymotrypsin-like proteasome inhibitor (CTRL)

Epoxomicin (CAS 134381-21-8)

Epoxomicin | CAS 134381-21-8 is rated 5.0 out of 5 by 1.
  • y_2018, m_11, d_14, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.9
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_201298, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 194ms
  • REVIEWS, PRODUCT
Application: A potent chymotrypsin-like proteasome inhibitor (CTRL)
CAS Number: 134381-21-8
Purity: ≥95%
Molecular Weight: 554.7
Molecular Formula: C28H50N4O7
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Epoxomicin is a potent proteasome inhibitor, primarily inhibiting the activity of CTRL(chymotrypsin-like proteasome). The novel α-epoxy ketone moiety of Epoxomicin forms covalent bonds with residues in particular catalytic subunits of the enzyme, disabling activity. The trypsin-like and peptidyl-glutamyl peptide hydrolyzing behavior of the proteasome were both inhibited by Epoxomicin as well (at 100 and 1,000-fold slower rates, respectively). Bone formation is heavily regulated by the ubiquitin-proteasome pathway, and Epoxomicin was shown to increase both bone volume and bone formation rates in rodents. Another study demonstrates that exposure to Epoxomicin and other proteasome inhibitors leads to dopaminergic cell death, producing a model of Parkinson's disease in vivo. Epoxomicin is an inhibitor of 20S Proteasome.


References

1. Hanada, M., et al. 1992. J. Antibiot. 45: 1746-1752. PMID: 1468981
2. Meng, L., et al. 1999. Proc. Natl. Acad. Sci. U.S.A. 96: 10403-10408. PMID: 10468620
3. Schwarz, K., et al. 2000. J. Immunol. 164: 6147-6157. PMID: 10843664
4. Princiotta, M.F., et al. 2001. Proc. Natl. Acad. Sci. U.S.A. 98: 513-518. PMID: 11149939
5. Garrett, I.R., et al. 2003. J. Clin. Invest. 111: 1771-1782. PMID: 12782679
6. McNaught, K.S., et al. 2004. Ann. Neurol. 56: 149-162. PMID: 15236415

Physical State :
Solid
Solubility :
Soluble in DMSO (10 mg/mL), and dichloromethane:methanol (9:1). Insoluble in water.
Storage :
Store at -20° C
Boiling Point :
~739.2° C at 760 mmHg (Predicted)
Density :
~1.1 g/cm3 (Predicted)
Refractive Index :
n20D 1.5
IC50 :
proteasome activity: IC50 = 4 nM; B16-F10, HCT116, and Moser solid tumor cells, as well as P388 and K562 leukemia cells: IC50 = 2-44 nM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
3035402
Merck Index :
14: 3630
MDL Number :
MFCD03791061
SMILES :
CC[C@H](C)[C@@H](C(=O)NC(=O)[C@H]([C@@H](C)O)NC(CC(C)C)C(=O)[C@]1(CO1)C)NC(=O)[C@H]([C@@H](C)CC)N(C)C(=O)C

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Epoxomicin  Product Citations

See how others have used Epoxomicin. Click on the entry to view the PubMed entry .

Citations 1 to 10 of 16 total

PMID: # 29127190  Pan, I. et al. 2017. FASEB J.

PMID: # 28667089  Molinski, SV. et al. 2017. EMBO Mol Med.

PMID: # 28451739  Luks, L. et al. 2017. Arch. Toxicol.

PMID: # 25264277  Lupino, E. et al. 2014. Biochemical pharmacology. 92: 235-50.

PMID: # 24385906  Caffarelli, N. et al. 2013. PLoS Pathog. 9: e1003825.

PMID: # 23604491  Orre, M. et al. 2013. Brain. 136: 1415-31.

PMID: # 24023882  Prasad, R. et al. 2013. PLoS ONE. 8: e73530.

PMID: # 22702336  Uyama, M. et al. 2012. Genes Cells. 17: 548-58.

PMID: # 18757370  Shi, W. et al. 2008. J. Biol. Chem. 283: 31608-31616.

PMID: # 16332688  Um, JW. et al. 2006. J. Biol. Chem. 281: 3595-3603.

Citations 1 to 10 of 16 total

How long will it remain stable in -20℃ DMSO?

Asked by: chemicalsmg
Thank you for your question. For epoxomicin, sc-201298, we do not recommend storing the aqueous solution for more than one day at -20℃.
Answered by: TechService7
Date published: 2017-01-03
  • y_2018, m_11, d_14, h_20CST
  • bvseo_bulk, prod_bvqa, vn_bulk_2.0.9
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_201298, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 221ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Shi Shi, et. al. (PubMed ID 18757370) used epoxomicin in their proteosome inhibition studies on MCF-7 cells. -SCBT Publication Review
Date published: 2015-04-09
  • y_2018, m_11, d_14, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.9
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_201298, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 74ms
  • REVIEWS, PRODUCT
--%>

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2018 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.